Neurotrophins and neurodegeneration

Neuropathology and Applied Neurobiology

Volumn 29, Issue 3, 2003, Pages 211-230

  Dawbarn, David ^a   Allen, S J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

ALS; Alzheimer's; Huntington's; Mimetics; Neuropathy; Neurotrophins; NGF; Parkinson's

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIPARKINSON AGENT; CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; COMPLEMENTARY DNA; DONEPEZIL; DOPAMINE; GALANTAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HUNTINGTIN; LEVODOPA; MESSENGER RNA; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PLACEBO; PROTEIN KINASE B; PROTEIN P75; RAS PROTEIN; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; RECOMBINANT NERVE GROWTH FACTOR; RECOMBINANT NEUROTROPHIN 3; RIVASTIGMINE; TACRINE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIABETES MELLITUS; DOPAMINERGIC NERVE CELL; DRUG SAFETY; FETAL TISSUE TRANSPLANTATION; HUMAN; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENTAL DISEASE; MOTOR NEURON DISEASE; MOUSE; MULTICENTER STUDY; NAUSEA; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; ONCOGENE; PARKINSON DISEASE; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY;

ANIMALS; HUMANS; NERVE DEGENERATION; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES; NEURONS; RECEPTORS, NERVE GROWTH FACTOR;

EID: 0038170540     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.2003.00487.x     Document Type: Review

References (219)

1. Alberch J. Pérez-Navarro E. Canals JM. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res Bull 2002: 57: 817-22
2. Allen SJ, Alzheimer's disease: past, present and future themes. In Neurobiology of Alzheimer's Disease 2nd edn, Eds D Dawbarn. SJ Allen. Oxford: Oxford University Press, 2001; 1-32
3. Allen SJ, Dawbarn D, MacGowan SH, Wilcock GK, Treanor JJS, Moss TH. A Quantitative morphometric analysis of basal forebrain neurones expressing B-NGF receptors in normal and Alzheimer's disease brains. Dementia 1990; 1: 125-37
4. Allen SJ, Dawbarn D, Spillantini MG, Goedert M, Wilcock GK, Moss TH, Semenenko, FM. The distribution of β-nerve growth factor receptors in the human basal forebrain. J Comp Neurol 1989; 289: 626-40
5. Allen SJ, MacGowan SH. Treanor JJS, Feeney R, Wilcock GK, Dawbarn D, Normal NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci Lett 1991: 131: 135-9
6. Allen SJ, Wilcock GK, Dawbarn D. Profound and selective loss of catalytic TrkB in Alzheimer's Disease. Biochem Biophys Res Comm 1999; 264: 648-51
7. Altar CA, Bakhit C. Receptor-mediated transport of human recombinant nerve growth factor from olfactory bulb to forebrain cholinergic nuclei. Brain Res 1991; 541: 82-8
8. Anand P, Warner G, Parrett A, Nerve growth factor related small fibre dysfunction in human diabetic polyneuropathy. Ann Neurol 1994; 36: 284A
9. Apfel SC, Nerve growth factor for the treatment of diabetic neuropathy: what went wrong what went right and what does the future hold? Int Rev Neurobiol 2002; 50: 393-413
10. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA, Arrieata JL, Artalejo FR. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998; 51: 695-702
11. Arrieata JL, Artalejo FR, Methodology, results, and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature. Age Ageing 1998; 27: 161-79
12. Banfield MJ, Naylor RL, Robertson AGS, Allen SJ, Dawbarn D, Brady RL. Specificity in neurotrophin: Trk-receptor interaction: the crystal structure of TrkB-d5 in complex with neurotrophin-4/5. Structure 2001: 9: 1191-9
13. Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J 1982; 1: 549-53
14. Barrett GL, Bartlett PF. The p75 nerve growth factor receptor mediates survival or death depending on the stage of sensory neuron development. Proc Nat Acad Sci 1994; 91: 6501-5
15. Bates GP, Mangiarini L, Davies SW. Transgenic mice in the study of polyglutamine repeat expansion diseases. Brain Pathol 1988; 8: 699-714
16. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. The ALS/riluzole Study Group. New Eng J Med 1994; 330: 585-9
17. Bentley CA, Lee KF. p75 is important for axon growth and Schwann cell migration during development. J Neurosci 2000; 20: 7706-15
18. Berkemeier LR, Ozcelik T, Francke U. Rosenthal A, Human chromosome 19 contains the neurotrophin-5 gene locus and three related genes that may encode novel acidic neurotrophins. Somat Cell Mol Genet 1992; 18: 233-45
19. Berkemeier LR, Winslow JW, Kaplan DR, Nikolics K, Goeddel DV, Rosenthal A. Neurotrophin-5: a novel neurotrophic factor that activates trk and trkB, Neuron 1991; 7: 857-66
20. Bibel M, Barde YA. Neurotrophin signal transduction in the nervous system. Genes Dev 2000; 14: 2919-57
21. Bibel M, Hoppe E, Barde YA. Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. EMBO J 1999; 18: 616-22
22. Bjorklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, Isacson O. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci 2002; 99: 2344-9
23. Blesch A, Conner JM, Tuszynski MH. Modulation of neuronal survival and axonal growth in vivo by tetracycline-regulated neurotrophin expression. Gene Ther 2001; 8: 954-60
24. Boissiere F, Faucheux B, Agid Y, Hirsch EC, Expression of catalytic trkB gene in the striatum and the basal forebrain of patients with Alzheimer's disease: an in situ hybridization study. Neurosci Lett 1997; 221: 141-4
25. Boissiere F, Faucheux B, Ruberg M, Agid Y, Hirsch EC. Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease. Expt Neurol 1997; 145: 245-52
26. Bothwell M, Functional interactions of neurotrophins and neurotrophin receptors. Ann Rev Neurosci 1995; 18: 223-53
27. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976; 99: 459-96
28. Bradley WG. A phase I/II study of recombinant brain-derived neurotrophic in patients with ALS. Ann Neurol 1995; 38: 971 (Abstract)
29. Bucker ED. Implantation of tumours in the hind limb field of the embryonic chick and the developmental response of the lumbosacral nervous system. Anat Rec 1948; 102: 369-89
30. Canals JM, Checa N, Marco S, Akerud P, Michels A, Perez-Navarro E, Tolosa E, Arenas E, Alberch J. Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. J Neurosci 2001; 21: 117-24
31. Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Nat Acad Sci 2002; 99: 12432-7
32. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A. Alzheimer-like neurodegeneration in aged anti-nerve growth factor transgenic mice. Proc Natl Assoc Sci 2000; 97: 6826-31
33. Carter BD, Kaltschmidt C, Kaltschmidt B, Offenhauser N, Bohm-Matthaei R, Baeuerle PA, Barde YA. Selective activation of NF-kappa B by nerve growth factor through the neurotrophin receptor p75. Science 1996; 272: 542-5
34. Casaccia-Bonnefil P, Carter BD, Dobrowsky RT, Chao MV. Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature 1996; 383: 716-9
35. Chao MV. The p75 neurotrophin receptor. J Neurobiol 1994; 42: 1373-85
36. Chao MV, Bothwell M. Neurotrophins: to cleave or not to cleave. Neuron 2002; 33: 9-12
37. Chen KS, Nishimura MC, Broz S. Assessment of learning and memory performance in mice heterozygous for nerve growth factor deletion. Soc Neurosci Abstract 1993; 19: 1963
38. Chen KS, Nishimura MC, Spencer S. Learning memory and the basal cholinergic system in aged mice heterozygous for nerve growth factor deletion. Soc Neurosci Abstract 1994; 28: 856
39. Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey II WH. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis 1998; 1: 35-44
40. Clary DO, Reichardt LF. An alternatively spliced form of the nerve growth factor receptor TrkA confers an enhanced response to neurotrophin 3. Proc Natl Acad Sci 1994; 91: 11131-7
41. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2: 806-19
42. Cohen S. Purification of a nerve growth promoting protein from the mouse submaxillary gland and its neurocytotoxic anti-serum. Proc Natl Acad Sci 1960; 46: 302-11
43. Connor B, Young D, Lawlor P. Trk receptor alterations in Alzheimer's disease. Mol Brain Res 1996; 42: 1-17
44. Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Mol Brain Res 1997; 49: 71-81
45. Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, Kilbridge JF, Carlson EJ, Epstein CJ, Mobley WC. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci 2001; 98: 10439-44
46. Crowley C, Spencer SD, Nishimura MC, Chen KS, Pitts-Meek S, Armantni MP, Ling LH, MacMahon SB, Shelton DL, Levinson AD. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 1994; 76: 1001-11
47. Crutcher KA, Scott SA, Liang S, Everson WV, Weingartner J. Detection of NGF-like activity in human brain tissue: Increased levels in Alzheimer's disease. J Neurosci 1993; 13: 2540-50
48. Davies P, Maloney AJF. Selective loss of central cholinergic neurones in Alzheimer's disease. Lancet 1976; II: 1403
49. Dawbarn D, Allen SJ, Semenenko FM. Immunohistochemical localization of α-nerve growth factor receptors in the forebrain of the rat. Brain Res 1988; 440: 185-9
50. Dawbarn D, Allen SJ, Semenenko FM. Coexistence of choline acetyltransferase and α-nerve growth factor receptors in the forebrain of the rat. Neurosci Lett 1988; 94: 138-4
51. Dawbarn D, De Quidt M, Emson PC. Survival of basal ganglia neuropeptide Y/somatostatin neurons in Huntington's disease. Brain Res 1985; 340: 251-60
52. Day-Lollini PA, Stewart GR, Taylor MJ, Johnson RM, Chellman GJ. Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor. Expt Neurol 1997; 145: 24-37
53. NTR. Novel functions and implications for diseases of the nervous system. Nat Neurosci 2001; 5: 1131-6
54. De Santis S, Pace A, Bove L, Cognetti F, Properzi F, Fiore M, Triaca V, Savarese A, Simone MD, Jandolo B, Manzione L, Aloe L. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 2000; 6: 90-5
55. Dunnett SB, Bjorklund A, Lindvall O. Cell therapy in Parkinson's disease - stop or go? Nat Rev Neurosci 2001; 2: 365-9
56. Dunnett SB, Whishaw IQ, Jones GH, Bunch ST. Behavioural biochemical and histochemical effects of different neurotoxic amino acids injected into the nucleus basalis magnocellularis of rats. Neuroscience 1987; 20: 653-69
57. Eide FF, Vining ER, Eide BL, Zang K, Wang XY, Reichardt LF. Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signalling. J Neurosci 1996; 16: 3123-39
58. Elias KA, Cronin MJ, Stewart TA, Carlsen RC. Peripheral neuropathy in transgenic diabetic mice, restoration of C-fiber function with human recombinant nerve growth factor. Diabetes 1998; 47: 1637-42
59. Ernfors P, Ibanez CF, Ebendal T, Olson L, Persson H. Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographical expression in the brain. Proc Natl Acad Sci 1990; 14: 5454-8
60. Espejo M, Cutillas B, Arenas TE, Ambrosio S. Increased survival of dopaminergic neurons in striatal grafts of fetal ventral mesencephalic cells exposed to neurotrophin-3 or glial cell line-derived neurotrophic factor. Cell Transplant 2000; 9: 45-53
61. Fahnestock M, Michalski B, Xu B, Coughlin MD. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 2001; 18: 210-20
62. Faradji V, Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand 1990; 81: 402-6
63. Fischer W, Bjorklund A, Chen K, Gage FH. NGF improves spatial memory in aged rodents as a function of age. J Neuroscience 1991; 11: 1889-906
64. Fischer W, Sirevaag A, Wiegand SJ, Lindsay RM, Bjorklund A. Reversal of spatial memory impairments in aged rats by nerve growth factor and neurotrophins 3 and 4/5 but not by brain-derived neurotrophic factor. Proc Natl Acad Sci 1994; 91: 8607-11
65. Fischer W, Wictorin K, Bjorklund A, Williams LR, Varon S, Gage FH. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987; 328: 65-8
66. Francke U, de Martinville B, Coussens L, Ullrich A. The human gene for the beta subunit of nerve growth factor is located on the proximal short arm of chromosome 1. Science 1983; 222: 1248-51
67. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-9
68. Gage FH, Armstrong DM, Williams LR, Varon S, Morphological response of axotomized septal neurons to nerve growth factor. J Comp Neurol 1988; 269: 147-55
69. Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, Bereznai B, Fabrizio E, Vieregge P, Horstmann RD. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998; 18: 262-5
70. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; in press.
71. Gnahn H, Hefti F, Heumann R, Schwab ME, Thoenen H. NGF-mediated increase of choline acetyltransferase ChAT in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain? Brain Res 1983; 285: 45-52
72. Goedert M, Fine A, Dawbarn D, Wilcock GK, Chao MV. NGF receptor mRNA distribution in human brain: normal levels in basal forebrain in AD. Mol Brain Res 1989; 5: 1-7
73. Goldberg J, Jin Q, Ambroise Y, Satoh S, Desharnais J, Capps K, Boger DL. Erythropoeitin mimetics derived from solution phase combinatorial libraries. J Am Chem Soc 2002; 124: 544-55
74. Goss JR, Goins WF, Lacomis D, Mata M, Glorioso JC, Fink DJ. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes 2002; 51: 2227-32
75. Gotz R, Koster R, Winkler C, Raulf F, Lottspeich F, Schart IM, Thoenen H. Neurotrophin-6 is a new member of the nerve growth factor family. Nature 1994; 372: 266-9
76. Granholm A-C, Mott JL, Bowenkamp K, Eken S, Henry S, Hoffer BJ, Lapchak PA, Palmer MR, van Horne C, Gerhardt GA. Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-hydroxydopamine lesioned striatum. Exp Brain Res 1997; 116: 29-38
77. Grondin R, Zhang Z, Yi A et al. Chronic controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002; 125: 2191-201
78. Guegan C, Vila M, Rosoklija G, Hays AP, Przedborski S. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 2001; 21: 6569-76
79. Haase G, Kennel P, Pettmann B, Vigne E, Akli S, Revah F, Schmalbruch H, Kahn A. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat Med 1997; 3: 429-36
80. Hallbook F, Ibanez CF, Persson H. Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in Xenopus ovary. Neuron 1991; 5: 845-58
81. Haque NSK, Hlavin M-L, Fawcett JW, Dunnett SB. The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease. Brain Res 1996; 712: 45-52
82. Haroutunian V, Kanof PD, Davis KL, Partial reversal of lesion-induced deficits in cortical cholinergic markers by nerve growth factor. Brain Res 1986; 386: 397-9
83. Hartikka J, Hefti F. Development of septal cholinergic neurons in culture; plating density and glial cells modulate effects of NGF on survival, fiber growth and expression of transmitter specific enzymes. J Neurosci 1988; 8: 2967-85
84. Hartikka J, Hefti F. Comparison of nerve growth factor effects on development of septum, striatum, and nucleus basalis cholinergic neurons in vitro. J Neurosci Res 1988; 21: 352-64
85. Hatanaka H, Tsukui H, Nihonmatsu I. Developmental change in nerve growth factor action from induction of choline acetyltransferase to promotion of cell survival in cultured basal forebrain cholinergic neurons from postnatal rats. Brain Res 1988; 467: 85-95
86. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurones after fimbrial transactions. J Neurosci 1986; 6: 2155-62
87. Hefti F, Mash DC. Localisation of nerve growth factor receptors in the normal human brain and in Alzheimer's disease. Neurobiol Ageing 1989; 10: 75-87
88. Hefti F, Hartikka J, Eckenstein F, Gnahn H, Heumann R, Schwab M. Nerve growth factor increases choline acetyltransferase but not survival or fiber outgrowth of cultured fetal septal cholinergic neurons. Neuroscience 1985; 14: 55-68
89. Hellweg R. Hartung HD. Endogenous levels of nerve growth factor NGF are altered in experimental diabetes mellitus a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 1990; 26: 258-67
90. Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 2000; 57: 846-51
91. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 1990; 9: 2459-64
92. Hoglinger GU, Sautter J, Meyer M, Spenger C, Seller RW, Oertel WH, Widmer HR. Rat ventral mesencephalon grown as solid tissue cultures: Influence of culture time and BDNF treatment on dopamine neuron survival and function. Brain Res 1998; 813: 313-22
93. Hogue-Angeletti R, Bradshaw RA. Nerve growth factor from mouse submaxillary gland: amino acid sequence. Proc Natl Acad Sci 1971; 68: 2417
94. Hohn A, Leibrock J, Bailey K, Barde YA. Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family. Nature 1990; 344: 339-41
95. Holden PH, Asopa V, Robertson AGS, Clarke AR, Tyler S, Bennett GS, Brain SD, Wilcock GK, Allen SJ, Smith SK, Dawbarn D. Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptor. Nature Biotech 1997; 15: 668-72
96. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 2002; 51: 783-6
97. Huebner K, Isobe M, Chao M, Bothwell M, Ross AH, Finan J, Hoxie JA, Sehgal A, Buck CR, Lanahan A. The nerve growth factor receptor gene is at human chromosome region 17q12-17q22, distal to the chromosome 17 breakpoint in acute leukemias. Proc Natl Acad Sci 1986; 83: 1403-7
98. Hynes MA, Poulsen K, Armanini M. Neurotrophin-4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures. J Neurosci Res 1994; 37: 144-54
99. Ivkovic S, Ehrlich ME. Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J Neurosci 1999; 19: 5409-19
100. Jaarsma D, Rognoni F, van Duijn W, Verspaget HW, Haasdijk ED, Holstege JC. CuZn superoxide dismutase SOD1 accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropath Berl 2001; 102: 293-305
101. Jacobsen J, Brimijoin S, Skau K. Retrograde transport of transmitter enzymes in streptozotocin-diabetic rats. Histochemistry 1981; 94: 659-66
102. Johansson M, Friedemann M, Hoffer B, Stromberg I. Effects of glial cell line-derived neurotrophic factor on developing and mature ventral mesencephalic grafts in oculo. Expneurol 1995; 134: 25-34
103. Johnson D, Lanahan A, Buck CR, Johnson D, Lanahan A, Buck CR, Sehgal A, Morgan C, Mercer E, Bothwell M, Chao M. Expression and structure of the human NGF receptor. Cell 1986; 47: 545-54
104. Eriksdotter Jonhagen ME, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, Olson L, Shigeta M, Theodorsson E, Viitanen M, Winblad B, Wahlund LO. Intracerbroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dementia Geriatric Cognitive Disorders 1998; 9: 246-57
105. Julien JP. Amyotrophic lateral sclerosis. Unfolding the toxicity of the misfolded. Cell 0000;104: 581-91
106. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000; 10: 381-91
107. Klein R, Jing SQ, Nanduri V, O'Rourke E, Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 1991; 65: 189-97
108. Klein R, Lamballe F, Bryant S, Barbacid M. The trkB tyrosine protein kinase is a receptor for neurotrophin-4. Neuron 1992; 8: 947-56
109. Klein R, Nanduri V, Jing SA, Lamballe F, Tapley P, Bryant S, Cordon-Cardo C, Jones KR, Reichardt LF, Barbacid M. The trkB tyrosine kinase is a receptor for brain derived neurotophic factor and neurotrophin-3. Cell 1991; 66: 395-403
110. Klein R, Parada LF, Coulier F, Barbacid M. trkB a novel protein tyrosine kinase receptor expressed during mouse neuronal development. EMBO J 1989; 8: 3701-9
111. Kordower J, Bartus RT, Bothwell M, Schatteman G, Gash DM. Nerve growth factor receptor immunoreactivity in the nonhuman primate Cebus apella: distribution morphology and colocalization with cholinergic enzymes. J Comp Neurol 1988; 277: 465-86
112. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290: 767-73
113. Kordower JH, Palfi S, Chen E-Y, Ma SY, Sendera T, Cochran EJ, Mufson EJ, Penn R, Goetz CG, Comella CD. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999; 46: 419-24
114. Korsching S, Auburger G, Heumann R, Korsching S, Auburger G, Heumann R, Scott J, Thoenen H. Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. EMBO J 1985; 4: 1389-93
115. Kostic V, Jackson-Lewis V, de Bilbao F. Dubois-Dauphin M, Przedborski S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997; 277: 559-62
116. Kromer LF. Nerve growth factor treatment after brain injury prevents neuronal death. Science 1987; 235: 214-6
117. Kust BM, Copray JC, Brouwer N, Troost D, Boddeke HW. Elevated levels of neurotrophins in human biceps brachii tissue of amyotrophic lateral sclerosis. Exp Neurol 2002; 177: 419-27
118. Lamballe F, Klein R, Barbacid M. trkC a new member of the trk family of tyrosine protein kinases is a receptor for neurotrophin-3. Cell 1991; 66: 967-9
119. Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, Thoenen H, Barde YA. Molecular cloning and expression of brain derived neurotrophic factor. Nature 1989; 341: 149-52
120. Levi-Montalcini R, Hamburger V. Selecting growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool 1951; 116: 321-62
121. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, Friedlander RM. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000; 288: 335-9
122. Liepinsch E, Ilag LL, Otting G, Ibanez CF. NMR structures of the death domain of the p75 neurotrophin receptor. EMBO J 1997; 16: 4999-5005
123. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurones. Science 1993; 260: 1130-2
124. Lin L-FH, Zhang TJ, Collins F, Armes LG. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J Neurochem 1994; 63: 758-68
125. McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen BA, Tucker T, Navia BA, Schifitto G, Katzenstein D, Rask C, Zaborski L, Smith ME, Shriver S, Millar L, Clifford DB, Karalnik IJ. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 2000; 54: 1080-8
126. Maisonpierre PC, Belluscio L, Friedman B, Alderson RF, Wiegand SJ, Furth ME, Lindsay RM, Yancopoulos GD. NT-3 BDNF and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron 1990; 5: 501-9
127. Maisonpierre PC, Belluscio L, Squinto S, Ip NY. Furth ME, Lindsay RM, Yancopoulos GD. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science 1990; 247: 1446-51
128. Maisonpierre PC, Le Beau MM, Espinosa R III, Ip NY, Belluscio L, de la Monte SM, Squinto S, Furth ME, Yancopoulos GD. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 1991; 10: 558-68
129. Mandel R, Gage FH, Thal LJ. Spatial learning in rats: correlation with cortical choline acetyltransferase and improvement with NGF following NBM damage. Exp Neurol 1989; 104: 208-17
130. Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 1986; 319: 743-8
131. Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M. Molecular and biochemical characterisation of the human trk proto-oncogene. Mol Cell Biol 1989; 9: 24-33
132. Martinez HJ, Dreyfus CF, Jonkait GM, Black IB. Nerve growth factor selectively increases cholinergic markers but not neuropeptides in rat basal forebrain culture. Brain Res 1987; 412: 295-301
133. Martinez-Serrano A, Bjorklund A. Immortalized neural progenitor cells for CNS gene transfer and repair. Trends Neurosci 1997; 20: 530-8
134. Mendez I, Dagher A, Hong M, Hebb A, Gaudet P, Law A, Weerasinghe S, King D, Desrosiers J, Darvesh S, Acorn T, Robertson H. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg 2000; 92: 863-9
135. Menzies FM, Ince PG, Shaw PJ. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Int 2002; 40: 543-51
136. Merlio J-P, Ernfors P, Jaber M, Persson H. Molecular cloning of rat trkC and identification of cells expressing mRNAs for members of the trk family in the rat central nervous system. Neuroscience 1992; 51: 513-32
137. Mesulam MM, Geula C. Nucleus basalis Ch4 and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988; 275: 219-40
138. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain, cytochemistry and cortical connections of the septal area diagonal band nuclei nucleus basalis substantia innominata and hypothalamus in the rhesus monkey. J Comp Neurol 1983; 214: 170-97
139. Meyer M, Johansen J, Gramsbergen JBG, Johansen TE, Zimmer J. Improved survival of embryonic porcine dopaminergic neurons in co-culture with a conditionally immortalized GDNF-producing cell line. Exp Neurol 2000; 164: 82-93
140. Meyer M, Matarredona ER, Seller RW, Zimmer J. Widmer HR. Additive effect of glial cell line-derived neurotrophic factor and neurotrophin-4/5 on rat fetal nigral explant cultures. Neuroscience 2001; 108: 273-84
141. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis ALS/motor neuron disease MND. Cochrane Database Syst Rev 2001: CD001447
142. Mizuno K, Carnahan J, Nawa H. Brain-derived neu rotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 1994; 165: 243-56
143. Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across sub-regions of the basal forebrain. Exp Neurol 1989; 105: 221-32
144. Mufson EJ, Kroin JS, Sendera TJ, Sobreviela T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 1999; 57: 451-84
145. Mufson EJ, Lavine N, Jaffar S, Kordower JH, Quirion R. Saragovi HU. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Expt Neurol 1997; 146: 91-103
146. Munoz DG, Greene C, Perl P, Selkoe DJ. Accumulation of phosphorylated neurofilaments in anterior horn motoneurones of amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol 1988; 47: 9-18
147. Mutoh T, Sobue G, Hamano T, Kuriyama M, Hirayama M, Yamamoto M, Mitsuma T. Decreased phosphorylation levels of TrkB neurotrophin receptor in the spinal cords from patients with amyotrophic lateral sclerosis. Neurochem Res 2000; 25: 239-45
148. Naruse S, Thinakaran G, Luo JJ. Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron 1998; 21: 1213-21
149. Naylor RL, Robertson AGS, Allen SJ, Sessions RB, Clarke AR, Mason GG, Burston JJ, Tyler SJ, Wilcock GK, Dawbarn D. A discrete domain of the human TrkB receptor defines the binding sites for brain derived neurotrophic factor and neurotrophin-4. Biochem Biophys Res Comm 2002; 291: 501-7
150. Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, Haigh J, Malta E, Traub M, Sendtner M, Toyka KV. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 201-6
151. Olson L, Nordberg A, Vonholst H, Backman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig P, Herlitz A, Lilja A. Nerve growth-factor affects C-11 nicotine binding blood-flow EEG and verbal episodic memory in an Alzheimer patient. J Neural Transm 1992; 4: 79-95
152. Orr H. Beyond the Qs in the polyglutamine diseases. Genes Dev 2001; 15: 925-32
153. Perez P, Coll PM, Hempstead BL. NGF binding to the trk tyrosine kinase receptor requires the extracellular immunoglobulin-like domains. Mol Cell Neurosci 1995; 6: 97-105
154. Perez-Navarro E, Alberch J, Neveu I, Arenas E. Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo. Neuroscience 1999; 91: 257-64
155. Perez-Navarro E, Canudas AM, Akerund P, Alberch J, Arenas E. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J Neurochem 2000; 75: 2190-9
156. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 1977; 34: 247-65
157. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991; 7: 695-702
158. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffer AA, Lazzarini AM, Nussbaum RL, Duvoisin RC. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996; 274: 1197-9
159. Pradat PF, Kennel P, Naimi-Sadaoui S, Finiels F, Orsini C, Revah F, Delaere P, Mallet J. Continuous delivery of neurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylamide neuropathies. Hum Gene Ther 2001; 12: 2237-49
160. Qureshi SA, Kim RM, Konteatis Z, Biazzo DE, Motamedi H, Rodrigues R, Boice JA, Calaycay JR, Bednarek MA, Griffin P, Gao YD, Chapman K, Mark DF. Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci 1999; 96: 12156-61
161. Radeke MJ, Misko TP, Hsu C, Herzenberg LA, Shooter EM. Gene transfer and molecular cloning on the rat nerve growth factor receptor. Nature 1987; 325: 593-7
162. Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, Wilcox HM, Flood DG, Beal MF, Brown RH Jr, Scott RW, Snider WD. Motor neurones in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death alter axonal injury. Nat Genet 1996; 13: 43-7
163. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Nat Acad Sci 1988; 85: 5733-7
164. Ridley RM, Murray TK, Johnson JA, Baker HF. Learning impairment following lesion of the basal nucleus of marmoset: modification by cholinergic drugs. Brain Res 1986; 376: 108-16
165. Riopelle J, Richardson PM, Verge VM. Distribution and characteristics of nerve growth factor binding on cholinergic neurons of rat and monkey forebrain. Neurochem Res 1987; 12: 923-8
166. Robberecht W. Genetics of amyotrophic lateral sclerosis. J Neurol 2000; 247: S6. VI/2-6
167. Robertson AGS, Banfield MJ, Allen SJ, Dando JA, Mason GG, Tyler SJ, Bennett GS, Brain SD, Clarke AR, Naylor RL, Wilcock GK, Brady RL, Dawbarn D. Identification and structure of the nerve growth factor binding site on TrkA, Biochem Biophys Res Comm 2001; 282: 131-41
168. Robinson RC, Radziejewski C, Stuart DJ, Jones EY. Structure of the brain-derived neurotrophic factor/neurotrophin 3 heterodimer. Biochemistry 1995; 34: 4139-46
169. Rodriguez-Tebar A, Dechant G, Barde YA. Binding of brain derived neurotrophic factor to the nerve growth factor receptor. Neuron 1990; 4: 487-92
170. Rogers BC. Development of recombinant human nerve growth factor rhNGF as a treatment for peripheral neuropathic disease. Neurotoxicology 1996; 17: 865-70
171. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentali A, Donaldson D, Goto J, O'Regan JP, Deng HX, Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62
172. Rosenblad C, Martinez-Serrano A, Bjorklund A. Glial cell line-derived neurotrophic factor increases survival growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 1996; 75: 979-85
173. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38: 73-84
174. Rowland LP, Scheider LA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688-700
175. Ruberti F, Capsoni S, Comparini A, Di Daniel E, Franzot J, Gonfloni S, Rossi G, Berardi N, Cattaneo A. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J Neurosci 2000; 20: 2589-601
176. Salehi A, Verhaagen J, Dijkhuizen PA, Swaab DF. Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience 1996; 75: 373-87
177. Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropath Appl Neurobiol 2001; 27: 257-74
178. Sautter J, Meyer M, Spenger C, Seiler RW, Widmer HR. Effects of combined BDNF and GDNF treatment on cultured dopaminergic midbrain neurons. Neuroreport 1998; 9: 1093-6
179. Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra CM, Rubin M, Cohen BA, Tucker T, Koralnik IJ, Katzenstein D, Haidich B, Smith ME, Shriver S, Millar L, Clifford DB, McArthur JC. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 2001; 57: 1313-6
180. Schneider R, Schweigwer A. A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors. Oncogene 1991; 6: 1807-11
181. Seiler M, Schwab ME. Specific retrograde transport of nerve growth factor NGF from neocortex to nucleus basalis in the rat. Brain Res 1984; 300: 33-9
182. Shelton DL, Sutherland J, Gripp J, Camerato T, Armanini MP, Phillips HS, Carroll K, Spencer SD, Levinson AD. Human trks: molecular cloning tissue distribution and expression of extracellular domain immunoadhesins. J Neurosci 1995; 15: 477-91
183. Sinclair SR, Svendsen CN, Torres EM, Martin D, Fawcett JW, Dunnett SB. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport 1996; 7: 2547-52
184. Smeyne RJ, Klein R, Schnapp A, Long LK, Bryant S, Lewin A, Lira SA, Barbacid M. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature 1994; 368: 246-9
185. Smith DE, Roberts J, Gage FH, Tuszynski MH. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci 1999; 96: 10893-8
186. Sobreviela T, Clary DO, Reichardt LF, Brandabur MM, Kordower JH, Mufson EJ. TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor choline acetyltransferase and serotonin. J Comp Neurol 1994; 350: 587-611
187. Spenger C, Hyman C, Studer L, Egli M, Evtouchenko L, Jackson C, Dahl-Jorgensen A, Lindsay RM, Seller RW. Effects of BDNF on dopaminergic serotonergic and GABAergic neurons in cultures of haman fetal ventral mesencephalon. Exp Neurol 1995; 133: 50-63
188. Spreux-Varoquaux O, Bensimon G, Lacomblez L, Pradat PF, Le Forestier N, Marouan A, Dib M, Meininger V. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 2002; 193: 73-8
189. Steininger TL, Wainer BH, Klein R, Steininger TL, Wainer BH, Klein R, Barbacid M, Palfrey HC. High-affinity nerve growth factor receptor Trk immunoreactivity is localized in cholinergic neurons of the basal forebrain and striatum in the adult rat brain. Brain Res 1993; 612: 331-5
190. Strohmaier C, Carter BD, Urfer R, Barde YA, Dechant GA. A splice variant of the neurotrophin receptor trkB with increased specificity for brain-derived neurotrophic factor. EMBO J 1996; 15: 3332-7
191. Studer L, Spenger C, Seller RW, Altar CA, Lindsay RM, Hyman C. Comparison of the effects of the neurotrophins on the morphological structure of dopaminergic neurons in cultures of rat substantia nigra. Eur J Neurosci 1995; 7: 223-33
192. Stuerenburg HJ, Kunze K. Tissue nerve growth factor concentrations in neuromuscular diseases. Eur J Neurol 1998; 5: 487-90
193. Summers WK. Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia Alzheimer type. New Engl J Med 1986; 315: 1241-5
194. Sutter A, Riopelle RJ, Harris-Warrick RM, Shooter EM. Characterisation of two distinct classes of binding sites on chick embryo sensory ganglia cells. J Biol Chem 1979; 254: 5972-892
195. Swerdlow RH, Parks JK, Cassarino DS, Trimmer PA, Miller SW, Maguire DJ, Sheehan JP, Maguire RS, Pattee G, Juel VC, Phillips LH, Turtle JB, Bennett JP Jr, Davis RE, Parker WD Jr. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol 1998; 153: 135-42
196. The BDNF Study Group Phase III. A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999; 52: 1427-33
197. Thorne RG, Frey WH. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001; 40: 907-46
198. Tian SS, Lamb P, King AG, Miller SG, Kessler L, Luengo JI, Averill L, Johnson RK, Gleason JG, Pelus LM, Dillon SB, Rosen J. A small nonpeptidyl mimic of granulocyte-colony-stimulating factor. Science 1998; 281: 257-9
199. Tomlinson DR, Fernyhough P, Diemel LT. Neurotrophins and peripheral neuropathy. Phil Trans R Soc Loud B Biol Sci 1996; 351: 455-62
200. Tomlinson DR, Fernyhough P, Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes 1997; 46: S43-9
201. Treanor JJS, Dawbarn D, Allen SJ, MacGowan SH, Wilcock GK. Nerve growth factor receptor binding in normal and Alzheimer's disease basal forebrain. Neurosci Lett 1991; 121: 73-6
202. Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ. Alpha- and beta-secretase: profound changes in Alzheimer's disease. Biochem Biophys Res Commun 2002; 239: 373-6
203. Ultsch MH, Wiesmann C, Simmons LC, Henrich J, Yang M, Reilly D, Bass SH, de Vos AM. Crystal Structures of the Neurotrophin-binding Domain of TrkA TrkB and TrkC. J Mol Biol 1999; 290: 149-59
204. Van Westerlaak MG, Bar PR, Cools AR, Joosten EA. Malonate-induced cortico-motoneuron death is attenuated by NT-4 but not by BDNF or NT-3. Neuroreport 2001; 12: 1355-8
205. Ventimiglia R, Mather P, Jones BE, Lindsay RM. The neurotrophins BDNF, NT-3 & NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur J Neurosci 1995; 7: 213-22
206. Vonsattel JP, DiFiglia M. Huntington disease. J Neurop Exper Neurol 1988; 57: 369-84
207. Walsh GS, Krol KM, Crutcher KA, Kawaja MD. Enhanced neurotrophin induced axon growth in myelinated portions of the CNS in mice lacking the p75 neurotrophin receptor. J Neurosci 1999; 19: 4155-68
208. Widmer HR, Schaller B, Meyer M, Seiler RW. Glial cell line-derived neurotrophic factor stimulates the morphological differentiation of cultured nigral calbindin and calretinin expressing neurons. Exp Neurol 2000; 164: 71-81
209. Wiedemann FR, Manfredi G, Mawrin C, Wiedemann FR, Manfredi G, Mawrin C, Beal MF, Schon EA. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem 2002; 80: 616-25
210. Wiesmann C, Ultsch MH, Bass SH, de Vos AM. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature 1999; 401: 184-8
211. Wilcock GK, Esiri MM, Bowen DM, Hughes AO. The differential involvement of subcortical nuclei in senile dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1988; 51: 842-9
212. Will B, Hefti F. Behavioral and neurochemical effects of chronic intraventricular-injections of nerve growth-factor in adult-rats with fimbria lesions. Behav Brain Res 1985; 17: 17-24
213. Williams LR, Varon S, Peterson, Wictorin K, Fischer W, Bjorklund A, Gage FH. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death alter fimbria fornix transaction. Proc Natl Acad Sci 1986; 83: 9231-5
214. Winkler J, Ramirez GA, Kuhn HG, Peterson DA, Day-Lollini PA, Stewart GR, Tuszynski MH, Gage FH, Thal LJ. Reversible schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann Neurol 1997; 41: 82-93
215. Wong PC, Cai H, Borchelt DR, Price DL. Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics. J Mol Neurosci 2001; 17: 233-57
216. Yiangou Y, Facer P, Sinicropi DV, Boucher TJ, Bennett DL, McMahon SB, Anand P. Molecular forms of NGF in human and rat nenropathic tissues: decreased NGF precursor-like immunoreactivity in human diabetic skin. J Periph Nerv Syst 2002; 7: 190-7
217. Yurek DM. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp Neurol 1998; 153: 195-202
218. Zuccato A, Ciammola D, Rigamonti BR, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E. Loss of Huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001; 293: 493-8
219. Zurn AD, Henry H, Schluep M, Aubert V, Winkel L, Eilers B, Bachmann C, Aebischer. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells. Cell Transplant 2000; 9: 471-84